Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

T. Shaw, Alice; Kim, Dong-Wan; Mehra, Ranee; S.W. Tan, Daniel; Felip, Enriqueta; Q.M. Chow, Laura; Ross Camidge, D.; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; J. Riely, Gregory; Solomon, Benjamin; Wolf, Juergen; Thomas, Michael; Schüler, Martin; Liu, Geoffrey; Santoro, Armando; Lau, Yvonne; A. Goldwasser, Meredith; Boral, Anthony; A. Engelman, Jeffrey

doi:10.1056/nejmoa1311107

Public

Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

Published in New England Journal of Medicine • Mar 26, 2014

Authors:

Alice T. Shaw

Dong-Wan Kim

Ranee Mehra

Abstract

BACKGROUND: Non-small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in pre...

Subject

Ceritinib

Crizotinib

Anaplastic lymphoma kinase

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!